| Cash Flow | 2025-09-30 |
|---|---|
| Net income | 1,965 |
| Depreciation and amortization | 803 |
| Stock-based compensation expense | 114 |
| Derivative warrant liabilities gain | 3,784 |
| Amortization of debt discount and issuance costs | 29 |
| Inventory write-down | 278 |
| Other non-cash adjustments | 0 |
| Non-cash adjustments from discontinued operations | 0 |
| Accounts receivable, net | 2,070 |
| Inventories | -1,056 |
| Prepaid expenses and other current assets | -484 |
| Accounts payable | 1,741 |
| Accrued liabilities | -1,637 |
| Other operating assets and liabilities, net | -403 |
| Changes in operating assets and liabilities from discontinued operations | 0 |
| Net cash used in operating activities | -618 |
| Cash received from sales of fixed assets | 0 |
| Cash payments for fixed asset purchases | 0 |
| Net cash provided by investing activities | 0 |
| Net proceeds received from revolving credit facility | 5,810 |
| Payment made to fixed payment arrangements | 3,050 |
| Payments made to borrowings | 464 |
| Net cash provided by financing activities | 2,296 |
| Net change in cash and cash equivalents | 1,678 |
| Cash and cash equivalents at beginning of period | 30,952 |
| Cash and cash equivalents at end of period | 32,630 |
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)